Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

Medicine & Life Sciences

• evacetrapib 100%
• Vascular Diseases 49%
• Placebos 27%
• Cholesterol Ester Transfer Proteins 16%
• LDL Cholesterol 10%
• HDL Cholesterol 10%
• Clinical Trials Data Monitoring Committees 8%
• Peripheral Vascular Diseases 6%
• Unstable Angina 6%
• Peripheral Arterial Disease 6%
• Cerebrovascular Disorders 5%
• Acute Coronary Syndrome 5%
• Coronary Artery Disease 4%
• Diabetes Mellitus 4%
• Cause of Death 4%
• Hospitalization 4%
• Cholesterol 4%
• Myocardial Infarction 4%
• Stroke 3%
• Lipids 3%
• Biomarkers 3%
• Confidence Intervals 3%
• Therapeutics 1%